Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • MEDI4736

    - PMLiVE

    Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients

    Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year

    - PMLiVE

    AstraZeneca’s Imfinzi/Imjudo regimen recommended by NICE to treat liver cancer

    Approximately 6,600 people are diagnosed with liver cancer every year in the UK

    EU flag

    CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

    Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

    - PMLiVE

    AstraZeneca shares late-stage results for Tagrisso combination in lung cancer

    An estimated 2.4 million people globally are diagnosed with lung cancer each year

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer

    Approximately 226,650 new cases of lung cancer will be diagnosed in the US this year

    - PMLiVE

    FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer

    ROS1-positive non-small cell lung cancer accounts for approximately 2% of new NSCLC cases

    - PMLiVE

    MHRA approves SFL’s Aumseqa to treat EGFR-mutated lung cancer in adults

    Approximately 43,000 people are diagnosed with lung cancer every year in the UK

    - PMLiVE

    Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC

    Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection

    - PMLiVE

    Johnson & Johnson’s subcutaneous Rybrevant granted EC approval to treat NSCLC

    It is hoped that the formulation will improve the treatment experience for patients

    - PMLiVE

    AstraZeneca’s Imfinzi regimen receives EC approval to treat resectable NSCLC

    More than 450,000 people are diagnosed with lung cancer every year in Europe

    - PMLiVE

    BMS receives positive CHMP opinion for perioperative Opdivo regimen in lung cancer

    Up to 55% of non-metastatic NSCLC patients will develop disease recurrence despite surgical resection

    - PMLiVE

    J&J shares overall survival results for Rybrevant/Lazcluze combination in lung cancer

    The regimen was approved by the MHRA earlier this month to treat EGFR-mutated NSCLC

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links